Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of an oral contraceptive (typically a combined estrogen-progestin formulation) and leuprolide, a gonadotropin-releasing hormone (GnRH) agonist. Oral contraceptives suppress ovulation and stabilize endometrial tissue through negative feedback on the hypothalamic-pituitary-ovarian axis, while leuprolide acts as a potent inhibitor of gonadotropin release, leading to decreased estrogen production. This combination may be used in the management of endometriosis-associated pelvic pain or for menstrual suppression in specific clinical scenarios. The rationale for combining these agents is to maximize suppression of ovarian function and control symptoms such as pain or abnormal bleeding[1][6][8]. Leuprolide is also commonly used with norethindrone acetate as "add-back" therapy to mitigate hypoestrogenic side effects; however, the use with combined oral contraceptives is less common but has been studied[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oral contraceptive + leuprolide.